To include your compound in the COVID-19 Resource Center, submit it here.

Calithera reports Phase I data for CB-839 combo in solid tumors

Calithera Biosciences Inc. (NASDAQ:CALA) reported data from 16 evaluable patients with advanced solid tumors in the

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE